Viatris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viatris (VTRS).

Price Target Range — 10 Quarters

Analyst Consensus — 10 Analysts

6Buy

3Hold

1Sell

Consensus RatingBuy# Analysts10Avg. Consensus PT$16Upside to Avg. PT-8.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$25
Sep 16, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$12→$13
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$20
Sep 8, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$15→$20
May 19, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$17→$22
May 8, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$17→$18
May 8, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$18→$20
Mar 24, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$15→$17
Jan 28, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$9→$12
Jan 16, 2026	Argus Research	—	Upgrade	Hold→Buy	$15
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$15
Oct 15, 2025	Truist Securities	Srikripa Devarakonda	Initiate	Buy	$15
Jun 6, 2025	Goldman Sachs	Matt Dellatorre	Initiate	Neutral	$10
Mar 7, 2025	Jefferies	Glen Santangelo	PT Cut	Buy	$15→$13
Mar 5, 2025	Piper Sandler	David Amsellem	PT Cut	Neutral	$14→$10
Feb 28, 2025	Barclays	Balaji Prasad	PT Cut	Underweight	$12→$9
Feb 28, 2025	B of A Securities	Jason Gerberry	PT Cut	Underperform	$11→$10
Dec 6, 2024	Piper Sandler	David Amsellem	PT Raise	Neutral	$13→$14
Nov 8, 2024	Barclays	Balaji Prasad	PT Raise	Underweight	$11→$12
Jul 19, 2024	Jefferies	Glen Santangelo	Reinstates	Buy	$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.

Avi Kapoor

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20

Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ratings page provides latest analyst takes on top stocks, sorted by accuracy. Ratings for three high-yielding health care stocks: VTRS, MDT, GSK. VTRS to report Q2 results on Aug.6, MDT recalls certain catheter system, GSK reports positive trial results. Benzinga Pro's newsfeed provides real-time alerts.

Avi Kapoor

Viatris Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Viatris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

People Also Watch

People Also Watch

Viatris Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Viatris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

PROPiper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

PROLeerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

PROArgus Research Maintains Buy on Viatris, Raises Price Target to $20

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20